{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:32:54Z","timestamp":1772515974980,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.acvd.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:32:59Z","timestamp":1670545979000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study"],"prefix":"10.1016","volume":"116","author":[{"given":"Patrick","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Lakhdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Detournay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2022.10.004_bib0110","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2022.10.004_bib0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-115-9-687","article-title":"Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study","volume":"115","author":"Wong","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2022.10.004_bib0120","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2022.10.004_bib0125","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.10.004_bib0130","series-title":"Hypercholesterolemia","author":"Ibrahim","year":"2022"},{"key":"10.1016\/j.acvd.2022.10.004_bib0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2022.10.004_bib0140","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2022.10.004_bib0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11883-020-00861-9","article-title":"The role of statins in current guidelines","volume":"22","author":"Rached","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.acvd.2022.10.004_bib0150","first-page":"139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.acvd.2022.10.004_bib0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.10.004_bib0160","article-title":"Arr\u00eat\u00e9 du 8 d\u00e9cembre 2020 relatif \u00e0 la proc\u00e9dure d\u2019accord pr\u00e9alable pour b\u00e9n\u00e9ficier de la prise en charge de la sp\u00e9cialit\u00e9 PRALUENT\u00ae (alirocumab)","volume":"0298","author":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","year":"2020","journal-title":"J Off Republique Fr"},{"key":"10.1016\/j.acvd.2022.10.004_bib0165","article-title":"Arr\u00eat\u00e9 du 20 juillet 2020 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux","volume":"0184","author":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","year":"2020","journal-title":"J Off Republique Fr"},{"key":"10.1016\/j.acvd.2022.10.004_bib0170","doi-asserted-by":"crossref","first-page":"e23445","DOI":"10.1097\/MD.0000000000023445","article-title":"Prevalence and management of hypercholesterolemia in France, the Esteban observational study","volume":"99","author":"Blacher","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acvd.2022.10.004_bib0175","first-page":"744","article-title":"Prevalence and treatment of familial hypercholesterolemia in France","volume":"35","author":"Berard","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2022.10.004_bib0180","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.10.004_bib0185","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.10.004_bib0190","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2022.10.004_bib0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5114\/aoms\/143476","article-title":"Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.acvd.2022.10.004_bib0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.acvd.2016.05.002","article-title":"Impact of a public media event on the use of statins in the French population","volume":"110","author":"Bezin","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2022.10.004_bib0205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u00a0\u2013\u00a0the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2022.10.004_bib0210","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521362200225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521362200225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:48:26Z","timestamp":1761745706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187521362200225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S187521362200225X"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2022.10.004","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}